Register Login

AVROBIO Inc (AVRO)

  • Event
  • May 17, 2022, 11:12 UTC

(10% Negative) AVROBIO, INC. (AVRO) Announces Delay in deficient Trials for Cystinosis Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 8:24 p.m.

    📋 AVROBIO, INC. (AVRO) - Clinical Trial Update

    Filing Date: 2022-05-17

    Accepted: 2022-05-17 07:12:07

    Event Type: Clinical Trial Update

    Event Details:

    AVROBIO Inc (AVRO) Announces Clinical Trial Update AVROBIO Inc (AVRO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: deficient, Society
    • Diseases/Conditions: Cystinosis, multiple tissues
    • Clinical Stage: Clinical Trial, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: SOC

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AVROBIO Inc
    • CIK: 0001681087
    • Ticker Symbol: AVRO
    • Period End Date: 2022-05-17
    • Document Type: 8-K

Search

News categories